Precision medicine and personalized breast cancer: Combination pertuzumab therapy

Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 1, 2014, Pages 95-105

  Reynolds, Kerry ^a   Sarangi, Sasmit ^a   Bardia, Aditya ^a   Dizon, Don S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

HER2 breast cancer; Personalized therapy; Pertuzumab; Precision medicine

Indexed keywords

ANTIBODY; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; PERTUZUMAB; PLACEBO; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADJUVANT THERAPY; ALOPECIA; ANAPHYLAXIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GENE SEQUENCE; HEART LEFT VENTRICLE FAILURE; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOPENIA; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84896960080     PISSN: None     EISSN: 11787066     Source Type: Book Series    
DOI: 10.2147/PGPM.S37100     Document Type: Review

References (68)

1. American Cancer Society. Cancer Facts and Figures: 2013-2014. Atlanta: American Cancer Society; 2013.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.
3. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985;230(4730):1132-1139.
4. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229(4717):974-976.
5. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312(5994):513-516.
6. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7(8):1120-1128.
7. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol. 1992;10(7):1044-1048.
8. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol. 1993;11(10):1936-1942.
9. Marks JR, Humphrey PA, Wu K, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994;219(4):332-341.
10. Pegram MD, Konecny G, Slamon D. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res. 2000;103:57-75.
11. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Onc. 2012;9(1):16-32.
12. Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010;21(9):944-950.
13. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463-475.
14. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93(24):1852-1857.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.
16. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672.
17. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14): 1273-1283.
18. McArthur HL, Mahoney KM, Morris PG, et al. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer. 2011;117(24):5461-5468.
19. Rodrigues MJ, Peron J, Frénel JS, et al. Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. Ann Oncol. 2013;24(4):916-924.
20. Mohd Sharial MS, Crown J, Hennessy BT. Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol. 2012;23(12):3007-3016.
21. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006;232(2):123-138.
22. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19): 1783-1791.
23. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317-328.
24. Kristjansdottir K, Dizon D. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers. Expert Opin Biol Ther. 2010;10(2):243-250.
25. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330-9336.
26. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64(7):2343-2346.
27. Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127-137.
28. Langdon SP, Faratian D, Nagumo Y, Mullen P, Harrison DJ. Pertuzumab for the treatment of ovarian cancer. Expert Opin Biol Ther. 2010;10(7):1113-1120.
29. Herbst RS, Davies AM, Natale RB, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007;13(20):6175-6181.
30. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28(7):1138-1144.
31. Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer. 2010;10(6):489-491.
32. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-119.
33. Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14(6): 461-471.
34. Ciruelos Gil EM, Brufsky A, Im YH, et al. Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab. J Clin Oncol. 2013;Suppl 31:600.
35. Baselga J, Cortés J, Im SA, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER-2-positive, first-line metastatic breast cancer (MBC). Cancer Res. 2012;72(Suppl 24): S5-S11.
36. Gianni L, Lladó A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(7): 1131-1137.
37. Cortés J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(14):1594-1600.
38. Bardia A, Baselga J. Preoperative chemotherapy for operable breast cancer. In: Lippman M, Harris J, Monica Morrow M, Osborne K, editors. Diseases of the Breast. Philadelphia: Lippincott Williams & Wilkins; 2013.
39. Reynolds KL, Bhatia A, Cheng X, et al. Neoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancer. J Clin Oncol. 2013;31 Suppl 26:147.
40. Bardia A, Greenup R, Moy B, et al. Pathological complete remission after neoadjuvant chemotherapy predicts improved survival in the various breast cancer subtypes: Systematic review and meta-analyses. Poster presented at: AACR Advances in Breast Cancer Research; October 12-15, 2011; San Francisco, CA.
41. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
42. Schneeweiss A, Chia S, Hickish T, et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res. 2011;71(Suppl 24):S5-S6.
43. Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236-244.
44. von Minckwitz G, Baselga J, Bradbury I, et al. OT1-02-04: adjuvant pertuzumab and herceptin in initial therapy of breast cancer: APHINITY (BIG 4-11/BO25126/TOC4939g). Cancer Res. 2011;71(Suppl 24):OT1-02-04.
45. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005;23(11):2534-2543.
46. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006;23(6):1275-1284.
47. Genentech. Perjeta [full prescribing information]. San Francisco: Genentech; 2012.
48. MotHER Pregnancy Registry. Available from: http://www.herceptinpregnancyregistry.com. Accessed January 16, 2014.
49. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8(5):459-465.
50. Perez EA. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer. 2008;8 Suppl 3:S114-S120.
51. US Food and Drug Administration. FDA approves Perjeta for neoadjuvant breast cancer treatment [press release]. Silver Spring, MD: FDA; September 30, 2013. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370393.htm. Accessed October 5, 2013.
52. US Food and Drug Administration. Pertuzumab [prescribing information]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125409s051lbl.pdf?et_cid=32583475&et_rid=463654371&linkid=+http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f125409s051lbl.pdf. Accessed on October 5, 2013.
53. Chernew ME, Newcomer LN, Swain SM. Treatment and cost implications of pertuzumab. Am J Manag Care. 2012;18(4): SP151-SP153.
54. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486(7403):405-409.
55. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013;31(15): 1834-1841.
56. Esteva FJ, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010;177(4):1647-1656.
57. Hanker AB, Pfefferle AD, Balko JM, et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci U S A. 2013;110(35):14372-14377.
58. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst. 2013;105(4):266-273.
59. Makhija S, Amler LC, Glenn D, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010;28(7):1215-1223.
60. Berghoff AS, Bago-Horvath Z, Preusser M, et al. Co-expression of HER3 in HER2-positive metastatic breast cancer patients is an independent predictor of impaired prognosis. Poster presented at: European Congress; September 27-October 1, 2013; Amsterdam, Netherlands.
61. Bardia A, Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res. 2013;19(23):6360-6370.
62. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med. 2012;366(26):2438-2441.
63. Untch M, von Minckwitz G. Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological. J Natl Cancer Inst Monogr. 2011;2011(43):138-141.
64. Rimawi MF, Mayer IA, Forero A, et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013;31(14):1726-1731.
65. DeMichele A, Berry DA, Zujewski J, et al. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013;19(11):2817-2823.
66. Hoffmann-La Roche. A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer. Available from: http://clinicaltrials.gov/show/NCT01358877. NLM identifier: NCT01358877. Accessed December 10, 2013.
67. Hoffmann-La Roche. A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE). Available from: http://clinicaltrials.gov/show/NCT01120184. NLM identifier: NCT01120184. Accessed December 10, 2013.
68. Hoffmann-La Roche. A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA). Available from: http://clinicaltrials.gov/show/NCT01026142. NLM identifier: NCT01026142. Accessed December 10, 2013.